{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:43Z","timestamp":1781636023934,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"French Ministry of Health (Programme Hospitalier de Recherche Clinique National (PHRC-N), 2019","award":["#AOM19025"],"award-info":[{"award-number":["#AOM19025"]}]},{"name":"Laboratoire FERRING"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prevalence of obesity in pregnancy is increasing worldwide, and it is associated with significant morbidity during labour and delivery. A benefit of increased doses of infused oxytocin during labour in obese women has been suggested by retrospective or underpowered studies. Thus, we aimed in a randomized double-blind controlled study at evaluating whether an increased oxytocin dose (compared to a standard dose) can reduce the rate of caesarean section without increasing maternal or neonatal morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PROXYMA is a French national multicentre, randomized, double-blind, controlled trial conducted in 14 maternity units. Adult primiparous obese women (body mass index\u2009\u2265\u200930\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) with singleton pregnancy, spontaneous or induced onset of labour, cephalic presentation and term, \u2265 37 weeks of gestation, will be included after informed consent. Exclusion criteria are medical contra-indication for oxytocin or hypersensitivity, previous coagulation disorders, foetal growth restriction (inferior to 5th percentile), foetal major malformation or heart rate abnormalities before use of oxytocin (at the time of inclusion), scarred uterus of gynaecological origin, planned caesarean section before labour, or severe renal failure. Patients will be randomized in a 1:1 ratio and receive either high-dose (experimental group) or standard-dose (control group) oxytocin from prescription until delivery, with increments at least every 20\u00a0min, and oxytocin will be stopped instantly at birth. The inclusion of the patient and randomization of the oxytocin dose to be administered will take place at the time of the oxytocin prescription. An \u201cout-of-protocol\u201d healthcare professional (midwife \/ nurse) will be in charge of the preparation of the treatment, in order to ensure the double-blind design. The primary outcome will be the caesarean section rate in each group. Secondary outcomes include the comparison of maternal, foetal and neonatal-related complications during labour and birth. We aim at including 882 women based on a reduction in caesarean section rate of 7% in the experimental group, with a power of 80% and an alpha risk of 5%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Comparing two different oxytocin doses will provide clinicians with better knowledge of labour management in obese primiparous women to reduce the number of caesarean sections and associated morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical Trials NCT04760496, registered on 18th february 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Project code number<\/jats:title>\n                    <jats:p>APHP200003 \/ EUDRACT No. : 2020-002640-23. Protocol Version N\u00b0 6.0 of 03\/09\/2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-026-08772-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:18:19Z","timestamp":1770794299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of increased oxytocin doses on the mode of delivery in obese primiparous women with spontaneous or induced labour. A double-blind, randomised, controlled trial (PROXYMA)"],"prefix":"10.1186","volume":"26","author":[{"given":"Julie","family":"Carrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre J.","family":"Vivanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Pizzagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Chastrusse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Benachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the collaborators of the PROXYMA trial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"8772_CR1","unstructured":"Enqu\u00eate nationale p\u00e9rinatale. 2021. Available from: https:\/\/www.santepubliquefrance.fr\/etudes-et-enquetes\/enquete-nationale-perinatale-2021. Cited 2023 Sep 19."},{"key":"8772_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1471-2458-7-168","volume":"7","author":"S Bhattacharya","year":"2007","unstructured":"Bhattacharya S, Campbell DM, Liston WA, Bhattacharya S. Effect of body mass index on pregnancy outcomes in nulliparous women delivering Singleton babies. BMC Public Health. 2007;7:168.","journal-title":"BMC Public Health"},{"issue":"9","key":"8772_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1055\/s-0031-1280852","volume":"28","author":"MJ Garabedian","year":"2011","unstructured":"Garabedian MJ, Williams CM, Pearce CF, Lain KY, Hansen WF. Extreme morbid obesity and labor outcome in nulliparous women at term. Am J Perinatol. 2011;28(9):729\u201334.","journal-title":"Am J Perinatol"},{"issue":"2","key":"8772_CR4","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.1016\/j.ajog.2012.06.044","volume":"207","author":"JR Chin","year":"2012","unstructured":"Chin JR, Henry E, Holmgren CM, Varner MW, Branch DW. Maternal obesity and contraction strength in the first stage of labor. Am J Obstet Gynecol. 2012;207(2):e1291\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"8772_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejogrb.2013.08.021","volume":"171","author":"S Carlh\u00e4ll","year":"2013","unstructured":"Carlh\u00e4ll S, K\u00e4ll\u00e9n K, Blomberg M. Maternal body mass index and duration of labor. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):49\u201353.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"15","key":"8772_CR6","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1080\/14767058.2017.1334046","volume":"31","author":"A Subramaniam","year":"2018","unstructured":"Subramaniam A, Owen J, Campbell SB, Harper LM, Fitzwater JL, Edwards RK. Maternal body mass index and oxytocin exposure in nulliparous women: is there an interaction associated with maternal and neonatal morbidities? J Matern Fetal Neonatal Med. 2018;31(15):2013\u20138.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"7","key":"8772_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jogoh.2017.06.007","volume":"46","author":"P Deruelle","year":"2017","unstructured":"Deruelle P, Servan-Schreiber E, Riviere O, Garabedian C, Vendittelli F. Does a body mass index greater than 25kg\/m2 increase maternal and neonatal morbidity? A French historical cohort study. J Gynecol Obstet Hum Reprod. 2017;46(7):601\u20138.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"6","key":"8772_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1800566","volume":"379","author":"WA Grobman","year":"2018","unstructured":"Grobman WA, Rice MM, Reddy UM, Tita ATN, Silver RM, Mallett G, et al. Labor induction versus expectant management in low-risk nulliparous women. N Engl J Med. 2018;379(6):513\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"8772_CR9","first-page":"517","volume":"49","author":"C Brien","year":"2021","unstructured":"Brien C, Bel S, Boudier E, Deruelle P. [Caesarean risk factors during labor for a class III obese nulliparous]. Gynecol Obstet Fertil Senol. 2021;49(6):517\u201321.","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"1","key":"8772_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/jmwh.12935","volume":"64","author":"JA Ellis","year":"2019","unstructured":"Ellis JA, Brown CM, Barger B, Carlson NS. Influence of maternal obesity on labor induction: a systematic review and meta-analysis. J Midwifery Womens Health. 2019;64(1):55\u201367.","journal-title":"J Midwifery Womens Health"},{"issue":"14","key":"8772_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1055\/s-0035-1563717","volume":"32","author":"S Ronzoni","year":"2015","unstructured":"Ronzoni S, Rosen H, Melamed N, Porat S, Farine D, Maxwell C. Maternal obesity class as a predictor of induction failure: a practical risk assessment tool. Am J Perinatol. 2015;32(14):1298\u2013304.","journal-title":"Am J Perinatol"},{"key":"8772_CR12","volume":"7","author":"S Kenyon","year":"2013","unstructured":"Kenyon S, Tokumasu H, Dowswell T, Pledge D, Mori R. High-dose versus low-dose oxytocin for augmentation of delayed labour. Cochrane Database Syst Rev. 2013;7:CD007201.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"8772_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jogoh.2017.09.002","volume":"46","author":"B Blondel","year":"2017","unstructured":"Blondel B, Coulm B, Bonnet C, Goffinet F, Le Ray C. Trends in perinatal health in metropolitan France from 1995 to 2016: results from the french national perinatal surveys. J Gynecol Obstet Hum Reprod. 2017;46(10):701\u201313.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"2","key":"8772_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1701-2163(16)34433-4","volume":"32","author":"GAL Davies","year":"2010","unstructured":"Davies GAL, Maxwell C, McLeod L, Gagnon R, Basso M, Bos H, et al. Ob\u00e9sit\u00e9 et grossesse. J Obstet Gynaecol Can. 2010;32(2):174\u201384.","journal-title":"J Obstet Gynaecol Can"},{"issue":"4","key":"8772_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xagr.2022.100094","volume":"2","author":"AI Girsen","year":"2022","unstructured":"Girsen AI, Leonard SA, Butwick AJ, Joudi N, Carmichael SL, Gibbs RS. Early postpartum readmissions: identifying risk factors at birth hospitalization. AJOG Glob Rep. 2022;2(4):100094.","journal-title":"AJOG Glob Rep"},{"issue":"8","key":"8772_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/sj.ijo.0801670","volume":"25","author":"NJ Sebire","year":"2001","unstructured":"Sebire NJ, Jolly M, Harris JP, Wadsworth J, Joffe M, Beard RW, et al. Maternal obesity and pregnancy outcome: a study of 287,213 pregnancies in London. Int J Obes Relat Metab Disord. 2001;25(8):1175\u201382.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"6","key":"8772_CR17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1097\/01.AOG.0000188387.88032.41","volume":"106","author":"HE Robinson","year":"2005","unstructured":"Robinson HE, O\u2019Connell CM, Joseph KS, McLeod NL. Maternal outcomes in pregnancies complicated by obesity. Obstet Gynecol. 2005;106(6):1357\u201364.","journal-title":"Obstet Gynecol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-026-08772-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-026-08772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:04:44Z","timestamp":1781633084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12884-026-08772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8772"],"URL":"https:\/\/doi.org\/10.1186\/s12884-026-08772-4","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PROXYMA trial was submitted and approved by:the Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM) (national agency for drug safety), approved on December 8th 2020the regional ethics committee \u00ab Comit\u00e9 de Protection des Personnes(CPP)\u201d (French official independent Committee for protection of persons involved in biomedical research), approved on December 14th 2020the Commission Nationale de l\u2019Information et des Libert\u00e9s (CNIL) (French data protection authority), registration number MR001the \u2018Groupe de Recherche en Gyn\u00e9cologie Obst\u00e9trique\u2019 (GROG, French group of researchers in gynecology and obstetrics), approved on June 22th 2018Informed written consent will be obtained from all participants. The study will be presented to the eligible patients at the time of the labour, during the inclusion visit, in order to validate the inclusion criteria. Information and consent forms will be given to the patient. After a reflection period of minimum 30\u00a0min, the patient will then be asked to sign the consent form. The inclusion and randomisation will then be pursued by the investigator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}